SynthesisScientific reports2026
The efficacy of disease-modifying therapies in patients with clinically isolated syndrome: a systematic review and network meta-analysis.
Synthesis in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Clinically isolated syndrome (CIS) is the initial clinical presentation that may indicate the development of multiple sclerosis (MS). While significant advancements have been made in the treatment of MS, there remains no definitive consensus on the effective treatment of CIS. Our study aims to evaluate the outcomes of disease-modifying therapies (DMTs) in the progression of CIS to clinically definite multiple sclerosis (CDMS) and to assess their efficacy in the treatment of CIS. A literature search was conducted through March 2024, focusing on immunotherapies that can treat CIS. The control group consisted of patients who received a placebo. The primary outcomes were the number of patients who converted to CDMS over the course of the study and the progression of the severity of disability in patients with MS using the Expanded Disability Status Scale (EDSS). The secondary outcomes included improvement in CIS symptoms based on MRI lesions, including gadolinium-enhancing (GDE) and T2-weighted (T2W) lesions. A total of 9 studies (8 randomized controlled trials and 1 post hoc analysis) included 3,339 patients diagnosed with CIS who received immunotherapy. The patients had a mean age of 31.4 ± 7.8 years and were followed for a mean duration of 35.7 months. Cladribine showed the strongest evidence in lowering CDMS conversion (HR 0.37; 95% CrI 0.23-0.59; SUCRA 85.40 followed by GA (HR 0.50; 95% CrI 0.34-0.73; SUCRA 62.10), IFN beta-1b (HR 0.51; 95% CrI 0.35-0.74; SUCRA 60.60), teriflunomide (HR 0.59; 95% CrI 0.37-0.92; SUCRA 59.20), and IFN beta-1a (HR 0.62; 95% CrI 0.50-0.77; SUCRA 39.50), respectively. DMTs, including cladribine, teriflunomide, IFN beta-1a, IFN beta-1b, and GA, showed evidence of reducing conversion to CDMS compared with placebo. Cladribine and GA showed the strongest evidence for a high probability of reducing CDMS conversion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.